全文获取类型
收费全文 | 2322篇 |
免费 | 118篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 116篇 |
妇产科学 | 56篇 |
基础医学 | 206篇 |
口腔科学 | 41篇 |
临床医学 | 131篇 |
内科学 | 322篇 |
皮肤病学 | 48篇 |
神经病学 | 114篇 |
特种医学 | 356篇 |
外科学 | 413篇 |
综合类 | 156篇 |
预防医学 | 104篇 |
眼科学 | 124篇 |
药学 | 158篇 |
1篇 | |
中国医学 | 9篇 |
肿瘤学 | 105篇 |
出版年
2023年 | 17篇 |
2022年 | 19篇 |
2021年 | 46篇 |
2020年 | 26篇 |
2019年 | 22篇 |
2018年 | 48篇 |
2017年 | 31篇 |
2016年 | 36篇 |
2015年 | 53篇 |
2014年 | 75篇 |
2013年 | 88篇 |
2012年 | 123篇 |
2011年 | 129篇 |
2010年 | 84篇 |
2009年 | 71篇 |
2008年 | 122篇 |
2007年 | 136篇 |
2006年 | 90篇 |
2005年 | 88篇 |
2004年 | 75篇 |
2003年 | 83篇 |
2002年 | 70篇 |
2001年 | 60篇 |
2000年 | 54篇 |
1999年 | 51篇 |
1998年 | 54篇 |
1997年 | 46篇 |
1996年 | 45篇 |
1995年 | 31篇 |
1994年 | 25篇 |
1993年 | 29篇 |
1992年 | 26篇 |
1991年 | 38篇 |
1990年 | 22篇 |
1989年 | 64篇 |
1988年 | 48篇 |
1987年 | 38篇 |
1986年 | 45篇 |
1985年 | 36篇 |
1984年 | 18篇 |
1983年 | 20篇 |
1982年 | 28篇 |
1981年 | 16篇 |
1980年 | 23篇 |
1979年 | 15篇 |
1978年 | 20篇 |
1977年 | 18篇 |
1976年 | 13篇 |
1975年 | 9篇 |
1973年 | 7篇 |
排序方式: 共有2470条查询结果,搜索用时 14 毫秒
41.
Recent work has shown that vasoactive intestinal peptide (VIP), one of the many candidate hormones of the gut, also occurs widely in neurones. To determine whether the neuronal peptide may have a neurotransmitter function, we studied changes in immunoreactive VIP in dog plasma and human cerebrospinal fluid after the infusion of choline esterase inhibitors (neostigmine and physostigmine, respectively). Immunoreactive VIP was released in both situations. The systemic changes (in VIP levels) were enhanced five weeks after portacaval shunting in dogs. Our results demonstrate that the immunoreactive VIP level increases as a result of choline esterase inhibitors. The plasma "release" may originate either from peripheral peptidinergic nerve terminals or from APUD cells of the gastroenteropancreatic system. The increase in immunoreactive cerebrospinal fluid VIP may very well originate from central neurons, since the peptide does not apparently cross the blood-brain barrier. 相似文献
42.
目的观察小分割分次立体定向放射治疗(fractionated stereotatic radiation therapy,FSRT)脑转移瘤的近期疗效.方法15例病人单纯全脑外照射(WBRT组),中间平面剂量20~40Gy/10~20次/2~4周.17例病人接受FSRT(FSRT组),每次分次剂量为2.5~3.0Gy.其中11病人行单纯FSRT,中心总剂量为30~60Gy/1 0~20次/2~4周;6例病人先行WBRT,然后行FSRT,中心总剂量为46~60Gy/5~6周.结果KSP评分增加10分以上者,WBRT组为5 3.3%,FSRT组为82.4%.(P<0.05).WBRT组有效率(CR PR)为50.0%;FSRT组有效率(CR PR)为80.0%.中位生存率:WBRT组为3.5月,FSRT组为10.0月.结论FSRT能有效地控制脑转移瘤,减轻神经系统症状,提高生存质量,延长病人生存期,而没有增加副作用,值得临床推广应用. 相似文献
43.
44.
45.
46.
Krumholtz JS Michalski JM Sundaram CP 《Journal of endourology / Endourological Society》2000,14(4):371-374
Health-related quality of life must be a factor when treatment options are discussed with a patient. Quality of life is measured by validated questionnaires that include generic and disease-targeted measures. Urinary and rectal symptoms and sexual function are evaluated after treatment for prostate cancer. Quality of life is adversely affected in the early post-brachytherapy period primarily by the urinary morbidity. Urinary symptoms peak 2 months after treatment and decline thereafter, although severe long-term urinary toxicity occurs in 3% to 12% of patients. Urinary symptoms are generally treated with alpha-blocker and anticholinergic drugs, but 2% to 5% of patients require transurethral resection of the prostate to relieve persistent obstruction. However, 6 months after treatment, overall satisfaction is excellent, and the majority of patients would recommend the procedure to a friend. 相似文献
47.
Ernest C Borden Laurence H Baker Robert S Bell Vivien Bramwell George D Demetri Burton L Eisenberg Christopher D M Fletcher Jonathan A Fletcher Marc Ladanyi Paul Meltzer Brian O'Sullivan David R Parkinson Peter W T Pisters Scott Saxman Samuel Singer Murali Sundaram Allan T van Oosterom Jaap Verweij Jill Waalen Sharon W Weiss Murray F Brennan 《Clinical cancer research》2003,9(6):1941-1956
Sarcomas--like leukemias, which are also mesodermal malignancies--carry biological significance disproportionate to their clinical frequency. Identification of mutations and translocations associated with these tumors has illuminated aberrant signaling pathways that cause these diseases, determine their behavior, and are therapeutic targets. Activated receptor-associated tyrosine kinase c-kit, mutated in most gastrointestinal stromal tumors, has proven a clinically effective target for enzyme inhibition. A translocation involving a single gene family, consisting of EWS and related genes, has been identified in five different sarcomas, and its chimeric protein products could prove similarly amenable to inhibitors. Resolution of the histopathological complexity is being aided by data from molecular and chromosomal characterization. Improvements in imaging, definition of prognostic factors, and surgical and radiotherapeutic treatment have resulted in improved local control. Continued progress will depend on further adapting the rapidly evolving technologies of genomics and proteomics. It will also depend upon accurate histopathological diagnosis based on validated reagents and consistent methodologies applied to adequate tissue samples derived from patients with complete clinical data. Finally, multicenter, coordinated trials, such as those that occurred with assessment of imatinib mesylate in metastatic gastrointestinal stromal tumors, will assure the most rapid reductions in morbidity and mortality. 相似文献
48.
49.
We compared the tumor-initiating activities toward mouse skin of two
structurally related polycyclic aromatic hydrocarbon diol epoxides: racemic
anti-1,2,3,4-tetrahydro-5,6-dimethylchrysene-1,2-diol-3,4- epoxide
(5,6-diMeCDE) and racemic anti-1,2,3,4-tetrahydro-5-
methylchrysene-1,2-diol-3,4-epoxide (5-MeCDE). Tumors induced by these diol
epoxides were analysed for mutations in the Ha-ras gene. 5,6- diMeCDE is
derived from the non-planar parent compound 5,6- dimethylchrysene, and
reacts to approximately equal extents with dA and dG in DNA, whereas
5-MeCDE is derived from a nearly planar parent compound, 5-methylchrysene,
and reacts mainly with dG in DNA. 5,6- diMeCDE, at initiating doses of 33,
100 or 400 nmol per mouse, induced 1.2, 2.2 and 6.2 skin tumors per mouse,
respectively. It was significantly less tumorigenic than 5-MeCDE which
induced 3.1, 7.5 and 9.1 skin tumors per mouse at the same doses. Tumors
induced by 5,6- diMeCDE had a large number of CAA-->CTA mutations in
codon 61 of the Ha- ras gene: 50, 55 and 75% of the tumors analysed had
this mutation at the 33, 100 and 400 nmol doses. No mutations were found in
codons 12 and 13 in the tumors induced by 5,6-diMeCDE. In contrast,
CAA-->CTA mutations in codon 61 were rarely seen in tumors induced by
5-MeCDE. At the highest dose of 5-MeCDE, 20% of the tumors analysed had
mutations at G of codons 12 and 13. The results of this comparative study
support the hypothesis that mutations in the Ha-ras gene in mouse skin
tumors induced by PAH diol epoxides occur as a result of their direct
reaction with the gene. However, pathways other than the commonly observed
Ha- ras codon 61 mutations are clearly important in mouse skin
tumorigenesis by these diol epoxides.
相似文献
50.